Bombay Biosyntex Chemicals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-07-2024
- Paid Up Capital ₹ 0.10 M
as on 17-07-2024
- Company Age 24 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -34.12%
(FY 2022)
- Profit -56.31%
(FY 2022)
- Ebitda -56.31%
(FY 2022)
- Net Worth 15.78%
(FY 2022)
- Total Assets 2.61%
(FY 2022)
About Bombay Biosyntex Chemicals
The Corporate was formerly known as Intelligent Trading Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jayant Ranade and Shraddha Dhamankar serve as directors at the Company.
- CIN/LLPIN
U74900MH2000PTC126639
- Company No.
126639
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 May 2000
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Bombay Biosyntex Chemicals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jayant Ranade  | Director | 01-Jan-2020 | Current |
| Shraddha Dhamankar | Director | 01-Jan-2020 | Current |
Financial Performance and Corporate Structure Insights of Bombay Biosyntex Chemicals.
Bombay Biosyntex Chemicals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 34.12% decrease. The company also saw a substantial fall in profitability, with a 56.31% decrease in profit. The company's net worth Soared by an impressive increase of 15.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bombay Biosyntex Chemicals?
In 2022, Bombay Biosyntex Chemicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nli Healthcare (India) Private LimitedActive 5 years 10 monthsJayant Ranade and Shraddha Dhamankar are mutual person
- Enem Nostrum Remedies Private LimitedActive 23 years 11 months
Shraddha Dhamankar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bombay Biosyntex Chemicals?
Unlock and access historical data on people associated with Bombay Biosyntex Chemicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bombay Biosyntex Chemicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bombay Biosyntex Chemicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
